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Methods and Results
Patients in the neurohumoral substudy (n=534) of the Survival and Ventricular Enlargement (SAVE) study had their neurohormones measured at baseline, 3, 12 and 24 months post-infarction, were followed 38 7 months and had these values related to prognosis. All patients had a left ventricular ejection fraction c40% early post-infarction. Atrial natriuretic peptide, aldosterone, norepinephrine and plasma renin activity decreased progressively over time. Patients with events had a persistent increase in these neurohormones with those dying within the first 24 months of follow-up having the greatest increase. Treatment with captopril affected only plasma renin activity (increase) and aldosterone (decrease). For patients who remained asymptomatic for the first 3 months postinfarction (n=471), by multivariate analyses (all neurohormones together with non-neurohumoral risk factors), 3-month plasma atrial natriuretic peptide and aldosterone were the most closely related to the development of severe heart failure or to the combined end-points (cardiovascular death, myocardial infarction, or severe heart failure). No neurohormone was related to recurrent myocardial infarction or to cardiovascular mortality. When the last neurohormone measured prior to an event was considered along with non-neurohumoral risk factors (adjusted univariate), atrial natriuretic peptide, aldosterone, norepinephrine and epinephrine were associated with prognosis indicating that a time-dependent analysis identified a closer relationship between neurohormones and events than that identified by 3-month values. However, by multivariate analyses atrial natriuretic peptide was the only neurohormone associated with an event, being associated with the development of severe heart failure (P<0·001) and the combined end-points (P=0·022). However, when neurohormones were considered as binary variables, activated or non-activated (defined as >1·96 SD above the mean of age-matched controls), an association between activation of norepinephrine prior to recurrent myocardial infarction (P<0·001) and combined end-points (P<0·01) and between activation of aldosterone and severe heart failure (P<0·05) was identified.
Introduction
In the acute phase of a myocardial infarction plasma renin activity and plasma levels of norepinephrine, atrial natriuretic peptide, endothelin and arginine vasopressin increase in most patients [1] [2] [3] [4] [5] . Until recently, this neurohumoral activation was considered to have disappeared by 7 to 10 days, except for persistent elevation of atrial natriuretic peptide in patients with systolic left ventricular dysfunction and persistent activation of plasma renin activity in patients with heart failure or using diuretic drugs [1] . The neurohumoral substudy of the Survival Revision submitted 30 March 1998, and accepted 4 April 1998.
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And Ventricular Enlargement (SAVE) trial, however, demonstrated that patients with asymptomatic left ventricular dysfunction present a whole spectrum of neurohumoral activation at a mean of 12 days after infarction, i.e. around the time of hospital discharge [2] . The pattern and extent of activation varied from patient to patient and could only partially be explained by clinical and laboratory variables, such as the use of diuretic drugs or the degree of left ventricular dysfunction. The evolution of neurohumoral activation beyond hospital discharge in post-infarction survivors with asymptomatic left ventricular dysfunction, however, is unknown. Furthermore, because the SAVE study demonstrated captopril to be beneficial in these patients, it can be conceived that this agent modifies the course of neurohumoral activation and that this is one of the mechanisms by which it is effective.
The degree of neurohumoral activation both during the first days of myocardial infarction in unselected populations of patients [3] [4] [5] [6] [7] [8] , and at the time of hospital discharge in patients with asymptomatic left ventricular dysfunction [9, 10] has incremental prognostic value. One would expect that persistent or new neurohumoral activation after hospital discharge in the latter group signifies a worse prognosis, but to our knowledge there is no direct evidence to support this. Comparison of the neurohumoral profile of asymptomatic patients with chronic left ventricular dysfunction [Studies Of Left Ventricular Dysfunction (SOLVD) prevention group] with those of SAVE suggest that some attenuation of post-infarction neurohumoral activation occurs with time. Alternatively, patients with early post-infarction asymptomatic left ventricular dysfunction could go one of two ways: maintain a state of more neurohumoral activation and evolve into patients with symptomatic left ventricular dysfunction, such as those of the SOLVD treatment group [11] , or reduce neurohumoral activation and evolve as patients such as the SOLVD prevention group [11] . Finally, although neurohumoral activation has prognostic significance in patients with left ventricular dysfunction early post-infarction [3] [4] [5] [6] [7] [8] [9] [10] and in patients with chronic left ventricular dysfunction [11] [12] [13] [14] [15] , differences in the relative importance of the various neurohormones exists. This suggests that early activation of some neurohormones is more frequently reduced during the first 3 months post-infarction and that these neurohormones may contribute to early remodelling and prognosis rather than to long-term prognosis. This has, however, not been evaluated.
Therefore, the objectives of the current study were to: (1) describe the temporal evolution of neurohumoral activation in survivors of myocardial infarction with left ventricular dysfunction who are initially asymptomatic and to relate these to prognosis, and (2) to assess the prognostic significance of neurohumoral measurements performed 3 months after the acute phase of a myocardial infarction and the temporal relationship between neurohormones and events in patients with left ventricular dysfunction who remained asymptomatic until then
Methods

Patients
The 534 patients included in the present study participated in the SAVE trial, a randomized, multicentre trial whose methods and results have been published in detail previously [16] [17] . In brief, 2231 patients with a left ventricular ejection fraction c40% by radionuclide ventriculography, but free of overt heart failure, were randomized to captopril or placebo 3 to 16 days after the qualifying myocardial infarction. Patients with contraindications to the use of an angiotensin converting enzyme (ACE) inhibitor, renal insufficiency (creatinine >2·5 mg . dl 1 ), severe valvular disease, refractory hypertension, malignancy or other conditions thought to limit survival, geographic problems, or inability or unwillingness to give informed consent, were excluded. Furthermore, patients with recurrent ischaemia or a positive exercise test had to undergo cardiac catheterization and, if indicated, a revascularization procedure in order to be eligible.
The patients agreeing to take part in the present study had additional blood samples drawn prior to randomization (mean, 12 days after myocardial infarction), and at 3 months, 1 year and 2 years after randomization to measure neurohormone levels. Blood was sampled from an indwelling venous cannula after the subjects had rested for 30 min in the supine position the morning after an overnight fast. The samples were frozen at 80 C and sent monthly to the central laboratory (Hô pital du Sacré-coeur de Montréal) packed in dry ice. Samples which took more than 24 h to reach the central laboratory, or which were haemolyzed or thawed, were not analysed. Previously described neurohormone assays [18, 19] were used to measure plasma renin activity and plasma concentrations of norepinephrine, atrial natriuretic peptide, arginine vasopressin, epinephrine, and aldosterone. The pattern of pre-randomization neurohumoral activation and its prognostic significance have been reported previously [2, 9] . A group of 38 agematched control subjects without known disease and not taking medication were used as normal values. Blood samples from these control subjects were obtained and processed in a manner identical to that used for the SAVE patients [2] . Values for these normal patients were: plasma norepinephrine 221 87 pg . ml 1 
End-points
The prospectively defined end-points were death, severe heart failure, recurrent myocardial infarction, and the combined end-points of death or severe heart failure or recurrent infarction, whichever occurred first. Deaths were assessed and classified by an independent committee. Severe heart failure was defined as heart failure requiring hospitalization or the use of openlabel ACE inhibition. Recurrent myocardial infarction was defined as a clinical myocardial infarction by the participating centre or the mortality committee.
Data analysis
All analyses were done on an intention-to-treat basis. Baseline characteristics of different patient categories were compared by use of two-sample t-tests for continuous variables and chi-square tests for categoric variables. For neurohormones at 3 months, a non-parametric Wilcoxon 2 sample test was also used and the P values presented with the median and 25th and 75th percentiles ( Table 3) .
To assess the evolution of neurohormonal levels as a function of time, the 534 study patients were classified into four groups according to whether they were randomized to captopril or placebo and whether they developed an end-point during the course of the study or not. The data were analysed using two-way analysis of variance (ANOVA) with repeated measurements on one factor, with the factors being group (four levels) and the repeated time factor (four levels). Because of missing data, the BMDP subprogram 5V was used to perform unbalanced repeated measures ANOVA using maximal likelihood techniques.
Assessment of the relationships between neurohumoral measurements at 3 months and the temporal relationship between neurohormone levels and subsequent end-points was restricted to patients who did not develop any end-point in the first 3 months. Both univariate and multivariate Cox proportional hazard models were used for analysis. The Cox proportional hazard model with time-dependent covariates was used to assess the temporal relationships between neurohormone levels and events. First univariate analyses were performed with each neurohormone as the only independent variable. Then eight other independent variables, chosen because they showed a strong univariate relationship with the end-points, were added to the model and adjusted univariate (with each neurohormone considered one at a time) and multivariate (all neurohormones considered together) analyses were carried out. These variables were: age; gender; history of myocardial infarction previous to the qualifying infarction; history of diabetes; history of hypertension prior to randomization; left ventricular ejection fraction prior to randomization; use of thrombolytic therapy; and randomization to captopril. Relative risk (more precisely, relative hazard), 95% confidence intervals (CI), and P values were derived from the regression coefficients of the independent variables. To allow comparison with the study of Benedict et al. [12] , we repeated the multivariate analyses with norepinephrine at 3 months as a binary variable (lower or higher than the median value) rather than as a continuous variable. To compare with our previous SAVE paper [9] we also reported the multivariate analyses with neurohormones as a binary variable (activated or not activated where activated is defined as being >1·96 SD above the mean for an age-matched population) [9] . All statistical analyses were performed using the SAS and BMDP software packages. The level of statistical significance was set at P<0·05. Table 1 shows the demographic, clinical and baseline neurohormonal characteristics of the entire SAVE neurohumoral substudy population. Of the 534 study patients, 263 were randomized to placebo and 271 to captopril. No differences were noted between patients randomized to captopril or placebo, except for atrial natriuretic peptide which was higher in patients randomized to captopril. The average length of follow-up was 38 7 months. Table 1 also indicates the percentage of patients in each treatment arm that developed an event.
Results
Patient characteristics and evolution
One hundred and sixty-eight of the patients randomized to placebo and 203 of those randomized to captopril remained event-free throughout the study. Sixty-nine patients died during the first 24 months of follow-up.
Of the 534 patients in the neurohumoral substudy, 61 developed at least one event and two were censored before 3 months. Table 2 shows the baseline clinical and 3 month end-point data of the 471 remaining patients. These are the patients used to evaluate the prognostic value of neurohormones in asymptomatic patients 3 months post-infarction. Patients asymptomatic at 3 months and randomized to captopril had lower cumulative occurrences of end-points during the rest of the study as compared to patients on placebo. However, this only reached statistical difference for severe heart failure. Three months post-infarction, patients randomized to captopril had higher plasma renin activity and lower plasma aldosterone levels ( Table 3) .
Evolution of neurohormones as a function of time, event and treatment group
If one excludes patients dying during the first 24 months of the study, most of the neurohormones decreased over time (Table 4 , Figs 1 and 2 ). This decrease was most consistent with aldosterone, norepinephrine and atrial natriuretic peptide and with plasma renin activity, varied according to event and treatment assignment. No consistent change in neurohormones over time could be documented for arginine vasopressin, and epinephrine. A consistent treatment effect on neurohormones was only noted for plasma aldosterone and renin activity. With all other neurohormones captopril had no consistent effect.
Patients who died prior to 24 months had markedly elevated neurohormones that did not decrease over time (Figs 1 and 2 ). This was particularly true for patients who died prior to 1 year, in which case neurohumoral activation, if anything, increased between baseline and 3 months. Patients having one of the combined events (death, severe heart failure or myocardial infarction) generally had greater neurohumoral activation than those that did not. This was particularly true for plasma renin activity, aldosterone, norepinephrine and atrial natriuretic peptide. This was less the case with arginine vasopressin and no difference was found for plasma epinephrine.
The interplay between time, event and treatment group is illustrated in Figs 1 and 2. Plasma renin activity increased in both placebo-and captopril-treated patients who had events, had an insignificant trend towards an increase in captopril-treated patients without an event and decreased in placebo-treated patients without an event. Aldosterone did not change significantly in placebo-treated patients whether they had an event or not; aldosterone remained elevated in placebo patients having events and lower in placebo patients not having events. Patients on captopril having an event tended to decrease aldosterone (P=0·07), with this decrease being significant in those on captopril having no event. Plasma 
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norepinephrine decreased in both placebo and captopriltreated patients who had no event. Patients having events had no change in plasma norepinephrine regardless of treatment group. If all four groups are taken individually, atrial natriuretic peptide did not change significantly regardless of group, although if all four groups are taken together, there was a decrease (P<0·001).
Three-month neurohormones and prognosis of asymptomatic patients
The univariate relationships between the plasma concentrations of neurohormones at 3 months after randomization and the occurrence of subsequent end-points in patients not having had an event in the first 3 months are presented in Table 5 . Cardiovascular mortality was correlated only with plasma concentrations of atrial natriuretic peptide. The occurrence of severe heart failure was correlated with plasma concentrations of norepinephrine, atrial natriuretic peptide, and aldosterone. No significant association with the occurrence of a recurrent myocardial infarction was found. Plasma concentrations of atrial natriuretic peptide, arginine vasopressin, and aldosterone were correlated with the occurrence of the combined end-points of cardiovascular death, severe heart failure or recurrent myocardial infarction. Table 4 also shows the results of the adjusted univariate [one neurohormone at a time added to the eight other independent variables known to modify survival (age, gender, history of myocardial infarction previous to the qualifying infarction, hypertension, diabetes, use of thrombolysis, use of captopril, and left ventricular ejection fraction)] and the multivariate analyses (all neurohormones together along with the eight other independent variables) of plasma neurohormone concentrations and prognosis. In general, adjusted univariate and multivariate analyses yielded similar results. No significant association between 3 month post-infarction norepinephrine as a binary variable, whether defined as above or below the median or activated (>1·96 SD above the mean) or non-activated and any of the end points, could be found.
Association between events and the last neurohormone value prior to the event
The univariate relationship between the plasma concentration of a neurohormone prior to an event and the subsequent event in patients that had remained asymptomatic for 3 months post-infarction are presented in Table 6 . Atrial natriuretic peptide, aldosterone, plasma renin activity and plasma epinephrine were related to all end-points, except for recurrent myocardial infarction. Arginine vasopressin measurements were not correlated to any end-point and no neurohormone correlated with recurrent myocardial infarction. These analyses were conducted in all patients who did not die during the first 24 months, n=454. Time refers to the change over time (baseline, 3, 12 and 24 months). Event refers to whether a patient had one of the combined end-points (death, severe heart failure or myocardial infarction) during the study or not. Treatment refers to whether a patient was randomized to captopril or placebo.
The adjusted (for the eight other important clinical variables) univariate relationship between the last neurohormone value prior to an event and an event was essentially the same as the unadjusted relationship, except for plasma renin activity, in which case the relationship was less marked, now being insignificantly associated with cardiovascular mortality.
The multivariate (considering all neurohormones together adjusted for the eight other important clinical variables) relationships between the last plasma concentration prior to an event and an event are also presented in Table 6 . Only very few significant relationships could be found, atrial natriuretic peptide being associated with severe heart failure and the combined end-points. Relationships with all other neurohormones did not reach statistical significance. Interestingly, dichotomizing norepinephrine into activated and non-activated rendered norepinephrine significantly correlated with recurrent myocardial infarction, RR=1·11 (95% CI: 1·05-1·19) P<0·001 and the combined events, RR=1·07, (95% CI: 1·02-1·12) P<0·01. Such an analysis did not modify the relationship with any other neurohormone except for aldosterone and severe heart failure RR=1·1, (95% CI: 1·10-1·21) P<0·05. 
Discussion
In previous analyses we determined that in some patients neurohumoral activation occurred a mean of 10 days post-infarction in patients with asymptomatic left ventricular dysfunction, and that this activation was associated with an independent risk of further cardiovascular events [9] . This study indicates that postinfarction patients with asymptomatic left ventricular dysfunction having an event in the first 3 months post-infarction have markedly elevated neurohumoral levels a mean of 10 days post-infarction. Those that remain asymptomatic for the first 3 months but go on to die or develop another cardiovascular end-point also have elevated neurohormones that persist throughout their period of survival or at least for the first 2 post-infarction years. Patients that have no cardiovascular event during a mean follow-up of 38 months post-infarction have lower neurohumoral values that decrease further over time. Captopril tends to attenuate the neurohumoral activation of patients having an event, this decrease being significant for plasma aldosterone. The addition of plasma neurohormones at 3 months to a multivariate model to predict cardiovascular events in patients asymptomatic 3 months post-infarction is useful for evaluating the risk of severe heart failure, or of combined cardiovascular end-points. Plasma atrial natriuretic peptide and to a lesser extent aldosterone were found to be most closely associated with these end points. Plasma norepinephrine was not. An association between elevated plasma neurohormones just prior to an event, and the subsequent event, occurred for most neurohormones. However, when added to a multivariate model which considers all neurohormones together with other prognostic variables, only plasma atrial natriuretic peptide, aldosterone and norepinephrine were associated with events. Thus, persistent neurohumoral activation occurs in some patients with post-infarction asymptomatic left ventricular dysfunction. This is an independent prognostic risk factor that may contribute to the poor evolution of some patients.
Neurohumoral evolution over time
Plasma norepinephrine values decreased over time, and rapidly normalized in patients having no event. Those surviving but having an event during the study maintained norepinephrine levels at the upper limit of normal. Patients dying during the first 24 months of follow-up had norepinephrine levels that, if anything, increased. Interestingly, norepinephrine levels were relatively lower 3 months post-infarction than they were in the SOLVD study [11] . Patients dying within 24 months post-infarction had levels similar to those of the SOLVD treatment group, those surviving 24 months but having an event during the study had levels similar to the SOLVD prevention group, while those having no event normalized plasma norepinephrine values. This difference in plasma norepinephrine values between patients in the SAVE and SOLVD studies was greater the further from the infarct that SAVE patients were considered. Why plasma norepinephrine values at 3 and 12 months post-infarction in the SAVE study were proportionately lower than those in the SOLVD studies is uncertain but may at least partially be the result of a slightly higher left ventricular ejection fraction in SAVE (31 7% vs Renin  0·050  1·08  1·00-1·17  0·086  1·08  0·99-1·18  0·185  1·08  0·96-1·22  Norepinephrine  0·458  1·07  0·89-1·30  0·862  1·02  0·82-1·26  0·990  1·00  0·81-1·24  ANP  0·007  1·07  1·02-1·11  0·196  1·04  0·98-1·09  0·145  1·05  0·99-1·11  AVP  0·217  1·03  1·00-1·08  0·567  1·02  0·97-1·07  0·588  1·02  0·96-1·07  Epinephrine  0·493  1·04  0·93-1·16  0·153  1·10  0·97-1·26  0·361  1·13  0·87-1·46  Aldosterone  0·070  1·10  0·99-1·22  0·228  1·07  0·96-1·20  0·155  1·13 0·95-1·34 Severe heart failure Severe heart failure Severe heart failure Renin
Combined end-points Combined end-points  Renin  0·135  1·04  0·99-1·11  0·137  1·05  0·985-1·11  0·492  1·03  0·95-1·12  Norepinephrine  0·194  1·08  0·96-1·20  0·556  1·04  0·917-1·18  0·834  0·99  0·86-1·13  ANP  0·001  1·07  1·04-1·10  0·001  1·06  1·024-1·09  0·001  1·06  1·03-1·10  AVP  0·013  1·04  1·01-1·06  0·231  1·02  0·988-1·05  0·460  1·01  0·98-1·04  Epinephrine  0·782  1·01  0·93-1·11  0·894  1·01  0·901-1·13  0·657  0·96  0·82-1·14  Aldosterone  0·001  1·11  1·04-1·17  0·020  1·08  1·012-1·15  0·019  1·12  1·02-1·22 ANP=atrial natriuretic peptide; AVP=arginine vasopressin; relative risk and confidence intervals are calculated for 1 standard deviation of the normal value for a specific neurohormone: plasma renin activity=1·2 ng . ml 1 . h 1 ; norepinephrine=87 pg . ml 1 ; ANP=9 pg . ml 1 ; AVP=0·3 pg . ml 1 ; epinephrine=16 pg . ml 1 ; aldosterone=7 ng . dl 1 . 29 5% in the SOLVD prevention group). Consistent with this is a comparison of the event rate in SAVE patients asymptomatic after 3 months to those of the SOLVD prevention group. In all cases, event rate was lower in SAVE (cardiovascular death 9% vs 13%, development of heart failure 12·5% vs 18% and myocardial infarction 7·6% vs 8·7%) despite a longer follow-up (35 months vs 31 months). Captopril had no effect on plasma norepinephrine values perhaps because the average values were so low [14, 20] . The evolution of plasma renin activity and plasma aldosterone over time in the placebo group was a good reflection of how a patient would evolve. Those who died during the first 24 months and those who had an event at any time during the study had persistently elevated levels while those that did not have an event quickly normalized both plasma renin activity and aldosterone. These results are consistent with numerous studies indicating a very poor prognosis in patients with persistent activation of the renin-angiotensin system [14, 15, 21] . Indeed, plasma renin and aldosterone levels in placebo patients showed the greatest discrepancy between patients having and not having events supporting an important pathophysiological role of these neurohormones for the development of cardiovascular events. When the mean values at 3 months of all patients on placebo were taken together, plasma renin values 3 months post-infarction in patients with left ventricular dysfunction but without overt heart failure were similar to those of the SOLVD prevention group, suggesting that chronic levels are relatively rapidly obtained postinfarction [11] . Captopril had the expected effects on these neurohormones: increasing plasma renin activity and decreasing plasma aldosterone. Although no escape from the effects of captopril on aldosterone levels could be noted, captopril only incompletely blocked this system as even on captopril, levels of these neurohormones were higher in patients having events.
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No consistent pattern for arginine vasopressin and epinephrine were noted. Three months postinfarction arginine vasopressin values were still on average nearly double those of control, a finding similar to that of the SOLVD treatment group [11] . Thereafter levels remained stable. Although patients dying or having events had markedly elevated mean arginine vasopressin values (1·5 pg . ml 1 to 2·5 pg . ml 1 ), because of the large standard deviation of these values, no consistent statistical difference between groups was found. As occurred with atrial natriuretic peptide, arginine vasopressin values did not normalize even in patients without events. Plasma epinephrine levels rapidly returned to within normal levels and remained there throughout the study. The only exception was in patients who died during the first 24 months, in which these values were very elevated, perhaps reflecting a high systemic adrenergic tone in these patients.
Prognostic value of neurohumoral activation at 3 months post-infarction in asymptomatic patients
Univariate analyses identified several 3-month postinfarction neurohormone levels as predictors of cardiovascular events. Their prognostic significance, however, disappeared after adjusting for other prognostically important factors by use of a multivariate model. The occurrence of severe heart failure, i.e. heart failure requiring hospitalization or the open-label use of ACE inhibitors, and the occurrence of the combined endpoints were significantly associated with plasma levels of atrial natriuretic peptide and aldosterone. Recurrent myocardial infarction was not correlated with any neurohormone. Plasma renin activity provides important prognostic information both in patients with chronic congestive heart failure due to systolic left ventricular dysfunction [11, 15, 21] and at the time of hospital discharge in post-infarction survivors with asymptomatic left ventricular dysfunction [9] . The reason for the lack of prognostic value of plasma renin activity at 3 months after randomization in the present study is probably the result of the effects of captopril on plasma renin activity. Captopril increased plasma renin activity and improved outcome in the group assigned to active treatment, thus dissociating the expected relationship between increased plasma renin activity and increased cardiovascular mortality and morbidity. Because only 4% of the patients in the placebo group had plasma renin activities higher than the mean plus 1·96 times the SD of our normal control subjects, any analysis restricted to the patients assigned to placebo would have been limited because of a too small number of patients sustaining events in the presence of increased plasma renin activity. Indeed, Benedict et al. found that plasma renin activity measured before randomization to placebo or enalapril was usually within the normal range and did not predict subsequent cardiovascular events in a population very similar to ours, those with left ventricular dysfunction but no overt heart failure [12] . Plasma aldosterone was, however, correlated with prognosis indicating that the renin-angiotensin-aldosterone system is related to prognosis. Such a relationship and the finding that captopril reduced aldosterone levels supports at least a partial neurohumoral mechanism of action for captopril and suggests that both plasma aldosterone and angiotensin II probably have some prognostic significance at 3 months post-infarction.
Benedict et al. found plasma norepinephrine to be the strongest predictor of clinical events in a subset of patients participating in the SOLVD prevention trial [12] . In the present study, however, norepinephrine measured 3 months post-infarction did not have any prognostic value at all, even when analyses were repeated with norepinephrine considered as a binary variable in a manner identical to that of Benedict et al., namely below or above the median value or according to whether activation (defined as >1·96 SD above the mean of normals) had occurred. The reasons for this discrepancy are unclear but some differences between the two populations do exist. First, in SAVE our patients had a slightly better left ventricular function than in SOLVD. Second, patients in SOLVD in many instances were far removed from an acute myocardial infarction, such that their mean values may have been more representative of a chronic stable state, while in SAVE the dynamic post-infarction process may not have been completed even 3 months post-infarction. Consistent with this is our finding that the adjusted univariate relationship between the last norepinephrine measurement and an event was significant for all events except for recurrent myocardial infarction.
In contrast to studies of patients with congestive heart failure due to systolic left ventricular dysfunction [13, 14] , atrial natriuretic peptide measured 3 months post-infarction in asymptomatic patient without left ventricular dysfunction did not predict mortality in the present study. Two reasons could explain these divergent results. First, many of the previous heart failure studies used only unadjusted univariate models, which did not correct for the potentially confounding effect of differences in baseline characteristics, to address the issue of the independent prognostic value of atrial natriuretic peptide. Indeed, in this study a significant association was found between plasma levels of atrial natriuretic peptide and survival by unadjusted univariate analysis, which is similar to the analysis performed in the heart failure studies, but not by adjusted univariate or multivariate analyses. Second, the majority of patients in this study had activation of atrial natriuretic peptide, rendering associations between plasma levels and mortality more difficult. In agreement with our findings, Benedict et al. found that atrial natriuretic peptide was not associated with cardiovascular mortality in a subset of patients participating in the SOLVD prevention trial [12] . Thus, elevations of atrial natriuretic peptide observed in patients with asymptomatic left ventricular dysfunction do not appear to be independently associated with cardiovascular death. However, using adjusted univariate and multivariate analyses, a significant association between atrial natriuretic peptide and the subsequent development of heart failure and of combined end points was found.
Last neurohormone level prior to an event and prognosis
To our knowledge, this is the first evaluation of the association between neurohormone levels prior to an event and the subsequent event in patients with asymptomatic left ventricular dysfunction at least 3 months post-infarction. This type of analyses has the advantage of considering the neurohormone levels closest to the event and thus the one most likely to have influenced the event.
As occurred with neurohormones 3 months postinfarction, by univariate analyses nearly all neurohormones were associated with all cardiovascular events except recurrent myocardial infarction. The exception was arginine vasopressin which correlated with nothing. However, contrary to measurements 3 months postinfarction, this close relationship between cardiovascular events and various neurohormones remained strong for plasma norepinephrine, atrial natriuretic peptide, aldosterone, and epinephrine even after adjusting for other important variables (adjusted univariate). This finding suggests that the relationship between neurohormones and cardiovascular events is best assessed by time-dependent analyses rather than by measurements at one point in time. Interestingly, using this type of analysis, the predictive value of norepinephrine approached that described by Benedict et al. [12] even when an adjusted univariate analysis was used. Nevertheless, when all neurohormones were considered, together with other independent variables, as occurred with 3-month measurements alone, the most important neurohormone appeared to be atrial natriuretic peptide.
Finally, we reported the time-dependent analysis of neurohormones and events using neurohormones as a binary variable, defined as activated and not activated, according to the definition used in our previous paper (c1·96 SD above the mean of normal patients) [19] . Using this definition and type of analyses we found a significant relationship between activation of norepinephrine and recurrent myocardial infarction and combined events in multivariate analyses. Such relationships are consistent with those of Benedict et al. [12] and suggest a potentially important pathophysiological role for norepinephrine in the subsequent occurrence of these events. Such relationships also present a pathophysiological rationale for the use of beta-blockers in these patients. Why we found a better relationship with norepinephrine using this type of analyses is uncertain, but again supports the use of time-dependent analyses and the importance of marked activation as opposed to mild activation as a risk factor for cardiovascular events.
Thus, neurohumoral activation post-infarction generally abates, except in patients that do poorly. Elevated neurohormones are associated with a poor prognosis and the predictive value of elevated, atrial natriuretic peptide and to a lesser extent aldosterone, norepinephrine and epinephrine are additive to these well-accepted risk factors.
Limitations of the study
Unfortunately we did not measure plasma brain natriuretic peptide and endothelin in this study. Also N-terminal ANP was only measured in a portion of the SAVE neurohumoral population such that this neurohormone was not included in our model. This is a clear limitation of our study.
